12.00-12.10 |
prof. MACIEJ MAŁECKIJagiellonian University, Kraków, Poland
|
opening the international conference |
Chairmen of the Session nr I |
|
|
12.10-12.30 |
prof. THIERRY FACONUniversity of Lille, CHU Lille, Service des Maladies du Sang, Lille, France |
“Immunotherapy for NDMM patients” |
12.30-12.40 |
discussion |
|
12.40-13.00 |
prof. ALESSANDRO GOZZETTIUniversity of Siena, Italy |
“Management of renal failure in plasma cell dyscrasias”
|
13.00-13.10 |
discussion |
|
13.10 13.30 |
prof. JENS HILLENGASSRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA |
“Navigating Modern Imaging Guidelines in Multiple Myeloma: Evidence vs. Real-World Practice” |
13.30-13.40 |
discussion |
|
13.40-14.00 |
MICHAELA HILLENGASS, RNRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA |
“Physical activity in multiple myeloma”
|
14.00-14.15 |
discussion |
|
14.15-15.00 |
COFFE BREAK |
|
Chairmen of the Session nr II |
prof. Tomasz Sacha
|
|
| 15.00-15.20 |
prof. JESUS G.BERDEJATenneesee Oncology and Sarah Cannon Research Institute, Nashville, TN, USA |
“How I treat AL AMYLOIDOSIS in 2027?" |
| 15.20-15.30 | discussion | |
15.30-15.50 |
prof. MICHEL DELFORGEDepartment of Hematology, Leuven University Hospital, Leuven, Belgium |
“Navigating Relapsed and Refractory Multiple Myleoma: Treatment Options and Sequencing in 2027”
|
15.50-16.00 |
discussion |
|
106.00-16.20 |
prof. GABOR MIKALADepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary |
“CELMoDs in Multiple Myleoma: Where Do They Fit in the Evolving Treatment Landscape” |
16.20-16.30 |
discussion |
|
| 16.30-16.50 |
prof. LAURENT GARDERETHôpital Saint Antoine, Sorbonne Université, Paris, France |
“The role of autologous stem cell transplantation in multiple myeloma in 2027” |
| 16.50-17.00 | discussion | |
17.00-17.20 |
prof. ARTUR JURCZYSZYNJagiellonian University, Kraków, Poland |
“The price of progress: managing treatment-related toxicity in multiple myleoma"
|
